nach oben

CNS Drugs

Erschienen in:

01.07.2019 | Review Article

Drug Treatment of Clinically Isolated Syndrome

verfasst von: Moritz Förster, Jonas Graf, Jan Mares, Orhan Aktas, Hans-Peter Hartung, David Kremer

Erschienen in: CNS Drugs | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that leads to inflammation, demyelination and ultimately axonal degeneration. In most cases, it is preceded by its precursor, clinically isolated syndrome (CIS) with conversion rates to clinically definite MS (CDMS) of roughly 20–75%. Neurologists are therefore faced with the challenge of initiating a disease-modifying therapy (DMT) as early as possible to favorably influence the course of the disease. During the past 20 years, a multitude of drugs have been incorporated into our therapeutic armamentarium for MS and CIS. Choosing the right drug for an individual patient is complex and should be based not only on the drug’s overall efficacy to prevent disease progression but also its specific adverse reaction profile, the severity of individual disease courses and, finally, patient compliance in order to adequately weigh associated risks and benefits. Here, we review the available data on the efficacy, safety and tolerability of DMTs tested for CIS and discuss their value regarding a delay of progression to CDMS.

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–36. https://doi.org/10.1016/S0140-6736(18)30481-1.PubMedCrossRef

Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13(7):700–22. https://doi.org/10.1111/j.1468-1331.2006.01342.x.PubMedCrossRef

Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288–99.PubMedCrossRef

Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007;61(6):504–13. https://doi.org/10.1002/ana.21141.PubMedCrossRef

Sadovnick A, Dyment D, Ebers G, Risch N, Group CCS. Evidence for genetic basis of multiple sclerosis. Lancet. 1996;347(9017):1728–30.PubMedCrossRef

Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25.PubMedCrossRef

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86. https://doi.org/10.1212/WNL.0000000000000560.PubMedPubMedCentralCrossRef

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–31. https://doi.org/10.1002/ana.410130302.PubMedCrossRef

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.PubMedCrossRef

10.

Brex PA, O’Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology. 1999;53(6):1184–90.PubMedCrossRef

11.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7.PubMedCrossRef

12.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–6. https://doi.org/10.1002/ana.20703.PubMedCrossRef

13.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. https://doi.org/10.1002/ana.22366.PubMedPubMedCentralCrossRef

14.

Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157–69. https://doi.org/10.1016/S1474-4422(11)70274-5.PubMedCrossRef

15.

Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease. Brain J Neurol. 2006;129(3):584–94. https://doi.org/10.1093/brain/awh721.CrossRef

16.

Thompson A, Polman C, Miller D, McDonald W, Brochet B, Filippi M, Montalban X, et al. Primary progressive multiple sclerosis. Brain J Neurol. 1999;120(6):1085–96.CrossRef

17.

Kaufman DW, Reshef S, Golub HL, Peucker M, Corwin MJ, Goodin DS, et al. Survival in commercially insured multiple sclerosis patients and comparator subjects in the US. Mult Scler Relat Disord. 2014;3(3):364–71. https://doi.org/10.1016/j.msard.2013.12.003.PubMedCrossRef

18.

Lunde HMB, Assmus J, Myhr KM, Bo L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621–5. https://doi.org/10.1136/jnnp-2016-315238.PubMedPubMedCentralCrossRef

19.

Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–9. https://doi.org/10.1212/01.wnl.0000237641.33768.8d.PubMedCrossRef

20.

Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11(1):33–41. https://doi.org/10.1016/S1474-4422(11)70262-9.PubMedCrossRef

21.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898–904. https://doi.org/10.1056/nejm200009283431301.PubMedCrossRef

22.

Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(10):977–86. https://doi.org/10.1016/S1474-4422(14)70191-7.PubMedCrossRef

23.

Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257–67. https://doi.org/10.1016/S1474-4422(14)70005-5.PubMedCrossRef

24.

Metz LM, Li DK, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, et al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med. 2017;376(22):2122–33.PubMedCrossRef

25.

Group IMSS. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655.CrossRef

26.

Paty D, Li DB, Group UMMS, Group IMSS. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis II MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):662.PubMedCrossRef

27.

Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol. 2008;255(4):480–7. https://doi.org/10.1007/s00415-007-0733-2.PubMedCrossRef

28.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389–97. https://doi.org/10.1016/S0140-6736(07)61194-5.PubMedCrossRef

29.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987–97. https://doi.org/10.1016/S1474-4422(09)70237-6.PubMedCrossRef

30.

Edan G, Kappos L, Montalban X, Polman CH, Freedman MS, Hartung HP, et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2014;85(11):1183–9. https://doi.org/10.1136/jnnp-2013-306222.PubMedCrossRef

31.

Kappos L, Edan G, Freedman MS, Montalban X, Hartung HP, Hemmer B, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87(10):978–87. https://doi.org/10.1212/WNL.0000000000003078.PubMedPubMedCentralCrossRef

32.

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain J Neurol. 2010;133(Pt 7):1914–29. https://doi.org/10.1093/brain/awq118.CrossRef

33.

Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain J Neurol. 2010;133(Pt 7):1900–13. https://doi.org/10.1093/brain/awq076.CrossRef

34.

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285–94.PubMedCrossRef

35.

O’Connor P, Kinkel RP, Kremenchutzky M. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Mult Scler J. 2009;15(6):728–34. https://doi.org/10.1177/1352458509103173.CrossRef

36.

O’Connor P. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther. 2003;25(11):2865–74.PubMedCrossRef

37.

Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. 2002;51(4):481–90.PubMedCrossRef

38.

Group CS. IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66(5):678–84.CrossRef

39.

Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O’connor PW, Simon JH, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol. 2012;69(2):183–90.PubMedCrossRef

40.

Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576–82.PubMedCrossRef

41.

Giovannoni G. The REFLEX study: a missed opportunity? Lancet Neurol. 2012;11(1):22–4. https://doi.org/10.1016/S1474-4422(11)70282-4.PubMedCrossRef

42.

Comi G, De Stefano N, Freedman MS, Barkhof F, Uitdehaag BM, de Vos M, et al. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry. 2017;88(4):285–94.PubMedCrossRef

43.

Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BM, et al. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. J Neurol. 2014;261(3):490–9.PubMedPubMedCentralCrossRef

44.

Sorensen PS. Neutralizing antibodies against interferon-beta. Ther Adv Neurol Disord. 2008;1(2):125–41. https://doi.org/10.1177/1756285608095144.PubMedCrossRef

45.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–76.PubMedCrossRef

46.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50(3):701–8.PubMedCrossRef

47.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503–11. https://doi.org/10.1016/S0140-6736(09)61259-9.PubMedCrossRef

48.

Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler J. 2012;19(8):1074–83. https://doi.org/10.1177/1352458512469695.CrossRef

49.

Bell C, Anderson J, Ganguly T, Prescott J, Capila I, Lansing JC, et al. Development of glatopa(R) (glatiramer acetate): the first FDA-approved generic disease-modifying therapy for relapsing forms of multiple sclerosis. J Pharm Pract. 2018;31(5):481–8. https://doi.org/10.1177/0897190017725984.PubMedCrossRef

50.

Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberye J, et al. Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial. JAMA Neurol. 2015;72(12):1433–41. https://doi.org/10.1001/jamaneurol.2015.2154.PubMedCrossRef

51.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–26.PubMedCrossRef

52.

Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e158.PubMedPubMedCentralCrossRef

53.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler J. 2018;24(12):1594–604.CrossRef

54.

Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler J. 2011;17(5):578–93.CrossRef

55.

Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, et al. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J. 2017;3(4):2055217317732802. https://doi.org/10.1177/2055217317732802.CrossRef

56.

O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–303. https://doi.org/10.1056/NEJMoa1014656.PubMedCrossRef

57.

Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–56. https://doi.org/10.1016/S1474-4422(13)70308-9.PubMedCrossRef

58.

Miller AE, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, et al. Outcomes of the TOPIC Extension Study of Teriflunomide in patients with early multiple sclerosis: up to 7 years of clinical results (P2.103). Neurology. 2017;88(16 Supplement):P2.103.

59.

Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain J Neurol. 2002;125(6):1297–308.CrossRef

60.

Metz LM, Eliasziw M. Trial of minocycline in clinically isolated syndrome of multiple sclerosis. N Engl J Med. 2017;377(8):789. https://doi.org/10.1056/NEJMc1708486.PubMedCrossRef

61.

Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399–402. https://doi.org/10.1038/82219.PubMedCrossRef

62.

Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, et al. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci. 2007;28(7):342–9. https://doi.org/10.1016/j.tips.2007.05.001.PubMedCrossRef

63.

Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78–84. https://doi.org/10.1038/nature01158.PubMedCrossRef

64.

Nath N, Giri S, Prasad R, Singh AK, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol. 2004;172(2):1273–86.PubMedCrossRef

65.

Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003;197(6):725–33. https://doi.org/10.1084/jem.20021425.PubMedPubMedCentralCrossRef

66.

Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, et al. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol. 2005;174(9):5630–5.PubMedCrossRef

67.

Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2015;29(4):277–91. https://doi.org/10.1007/s40263-015-0239-x.PubMedCrossRef

68.

Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390–5. https://doi.org/10.1212/01.wnl.0000319698.40024.1c.PubMedCrossRef

69.

Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing–remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010;16(4):450–4. https://doi.org/10.1177/1352458509358909.PubMedCrossRef

70.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, et al. Simvastatin treatment in patients with relapsing–remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010;16(7):848–54. https://doi.org/10.1177/1352458510369147.PubMedCrossRef

71.

Sorensen PS, Lycke J, Eralinna JP, Edland A, Wu X, Frederiksen JL, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691–701. https://doi.org/10.1016/S1474-4422(11)70144-2.PubMedCrossRef

72.

Kamm CP, El-Koussy M, Humpert S, Findling O, von Bredow F, Burren Y, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. J Neurol. 2012;259(11):2401–13. https://doi.org/10.1007/s00415-012-6513-7.PubMedPubMedCentralCrossRef

73.

Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, et al. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study). Mult Scler. 2016;22(9):1163–73. https://doi.org/10.1177/1352458515611222.PubMedCrossRef

74.

Kamm CP, El-Koussy M, Humpert S, Findling O, Burren Y, Schwegler G, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS One. 2014;9(1):e86663. https://doi.org/10.1371/journal.pone.0086663.PubMedPubMedCentralCrossRef

75.

Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383(9936):2213–21. https://doi.org/10.1016/S0140-6736(13)62242-4.PubMedCrossRef

76.

Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 2017;16(8):591–600. https://doi.org/10.1016/S1474-4422(17)30113-8.PubMedPubMedCentralCrossRef

77.

Tsakiri A, Kallenbach K, Fuglo D, Wanscher B, Larsson H, Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler. 2012;18(1):72–81. https://doi.org/10.1177/1352458511415452.PubMedCrossRef

78.

Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012;78(15):1171–8. https://doi.org/10.1212/WNL.0b013e31824f7fdd.PubMedPubMedCentralCrossRef

79.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189–99. https://doi.org/10.1016/S1474-4422(16)30377-5.PubMedCrossRef

80.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, et al. Predictors of response to opicinumab in acute optic neuritis. Ann Clin Transl Neurol. 2018;5(10):1154–62. https://doi.org/10.1002/acn3.620.PubMedPubMedCentralCrossRef

81.

Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004–15.PubMedCrossRef

82.

Grytten Torkildsen N, Lie S, Aarseth J, Nyland H, Myhr K. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler J. 2008;14(9):1191–8.CrossRef

83.

Brønnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain : a journal of neurology. 2004;127(4):844–50.CrossRef

84.

Stankoff B, Mrejen S, Tourbah A, Fontaine B, Lyon-Caen O, Lubetzki C, et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology. 2007;68(10):779–81.PubMedCrossRef

85.

Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F, Group L. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008;15(9):916–21.PubMedCrossRef

86.

Tremlett H, Zhao Y, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler J. 2008;14(3):314–24.CrossRef

87.

Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain J Neurol. 2003;126(4):770–82.CrossRef

88.

Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain J Neurol. 2008;131(Pt 3):808–17. https://doi.org/10.1093/brain/awm329.CrossRef

89.

Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2003;9(3):260–74. https://doi.org/10.1191/1352458503ms914oa.PubMedCrossRef

90.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015;21(8):1013–24. https://doi.org/10.1177/1352458514568827.PubMedCrossRef

91.

Mowry EM, Pesic M, Grimes B, Deen SR, Bacchetti P, Waubant E. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol. 2009;256(7):1061–6. https://doi.org/10.1007/s00415-009-5063-0.PubMedPubMedCentralCrossRef

92.

Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y, Robertson NP, Scolding NJ. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry. 2009;80(3):292–6.PubMedCrossRef

93.

Masjuan J, Alvarez-Cermeno J, Garcia-Barragan N, Diaz-Sanchez M, Espiño M, Sadaba M, et al. Clinically isolated syndromes A new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006;66(4):576–8.PubMedCrossRef

94.

Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84(8):909–14.PubMedCrossRef

95.

Rasche L, Scheel M, Otte K, Althoff P, van Vuuren AB, Giess RM, et al. MRI markers and functional performance in patients with CIS and MS: a cross-sectional study. Front Neurol. 2018;9:718. https://doi.org/10.3389/fneur.2018.00718.PubMedPubMedCentralCrossRef

96.

Pérez-Miralles F, Sastre-Garriga J, Tintoré M, Arrambide G, Nos C, Perkal H, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler J. 2013;19(14):1878–86. https://doi.org/10.1177/1352458513488231.CrossRef

97.

Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry. 2008;79(11):1236–44.PubMedPubMedCentralCrossRef

98.

Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, et al. Brain atrophy 15 years after CIS: baseline and follow-up clinico-radiological correlations. Mult Scler. 2018;24(6):721–7. https://doi.org/10.1177/1352458517707070.PubMedCrossRef

99.

Håkansson I, Tisell A, Cassel P, Blennow K, Zetterberg H, Lundberg P, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosis. Eur J Neurol. 2017;24(5):703–12.PubMedCrossRef

100.

Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2016;87(2):126–9. https://doi.org/10.1136/jnnp-2014-309690.PubMedCrossRef

101.

Dalla Costa G, Martinelli V, Sangalli F, Moiola L, Colombo B, Radaelli M, et al. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology. 2019;78:89. https://doi.org/10.1212/WNL.0000000000006902.CrossRef

102.

Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler J. 2013;19(2):188–98.CrossRef

103.

Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, et al. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler. 2012;18(10):1466–71. https://doi.org/10.1177/1352458512442438.PubMedPubMedCentralCrossRef

104.

Lebrun C, Bensa C, Debouverie M, Wiertlevski S, Brassat D, de Seze J, et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol. 2009;66(7):841–6.PubMedCrossRef

105.

Rossi S, Motta C, Studer V, Macchiarulo G, Germani G, Finardi A, et al. Subclinical central inflammation is risk for RIS and CIS conversion to MS. Mult Scler J. 2015;21(11):1443–52. https://doi.org/10.1177/1352458514564482.CrossRef

106.

Amato MP, Hakiki B, Goretti B, Rossi F, Stromillo ML, Giorgio A, et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology. 2012;78(5):309–14. https://doi.org/10.1212/WNL.0b013e31824528c9.PubMedCrossRef

107.

Knier B, Berthele A, Buck D, Schmidt P, Zimmer C, Mühlau M, et al. Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination. Mult Scler J. 2016;22(7):893–900.CrossRef

108.

Labiano-Fontcuberta A, Benito-León J. Radiologically isolated syndrome should be treated with disease-modifying therapy—no. Mult Scler J. 2017;23(14):1820–1.CrossRef

109.

Okuda DT. Radiologically isolated syndrome should be treated with disease-modifying therapy—yes. Mult Scler J. 2017;23(14):1818–9.CrossRef

110.

Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain J Neurol. 2002;125(10):2202–12.CrossRef

111.

Fialová L, Bartos A, Švarcová J, Zimova D, Kotoucova J, Malbohan I. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol. 2013;262(1–2):113–20.PubMedCrossRef

112.

Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing–remitting multiple sclerosis. J Neurochem. 2017;141(2):296–304.PubMedCrossRef

Titel: Drug Treatment of Clinically Isolated Syndrome
verfasst von: Moritz Förster
Jonas Graf
Jan Mares
Orhan Aktas
Hans-Peter Hartung
David Kremer
Publikationsdatum: 01.07.2019
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 7/2019
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-019-00647-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Post-Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in Adults with Attention-Deficit/Hyperactivity Disorder

Endolysosome and Autolysosome Dysfunction in Alzheimer’s Disease: Where Intracellular and Extracellular Meet

Rotigotine Transdermal Patch: A Review in Parkinson’s Disease

Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1

Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study